FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

[News]

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

More... (http://www.news-medical.net/news/20110630/FDAs-ODAC-recommends-withdrawal-of-Avastin-approval-for-metastatic-breast-cancer.aspx)